CI

At a glance

ClinicalIndex Comparison Record
N/ARecruiting· 397 target
Drug / intervention
MR-guided Linacradiation
Likely dose
Not stated in record
Key inclusion· 4
  • ✓Confirmed malignancy requiring stereotactic body radiation therapy
  • ✓Tumor size ≤7cm
  • ✓Age 18 years or older
  • ✓Ability to understand and sign written informed consent
Key exclusion· 4
  • ✕History of allergic reactions to gadolinium-based IV contrast
  • ✕Pregnant women
  • ✕Severe claustrophobia or anxiety
  • ✕Cannot undergo MRI

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04115254
NCT04115254N/ARecruitingHigh MomentumUpdated 7mo ago
Long Recruiting
CompareCT.gov

A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)

Dana-Farber Cancer Institute·interventional·Posted Oct 3, 2019·Updated Nov 13, 2025

In Brief

A clinical study evaluating MR-guided Linac for Pancreas Cancer and 12 related conditions. Currently recruiting, targeting 397 participants across 2 sites.

Signals

Enrolling ahead of pace

Detailed Summary

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreas Cancer, Lung Cancer, Renal Cancer, Adrenal Metastases, Prostate Cancer, Liver Metastases, Oligoprogressive Nodal Metastases, Metachronous Nodal Metastases, Synchronous Nodal Metastases, Mesothelioma, Spine Metastases, Brain Metastases, Borderline Resectable Pancreatic Carcinoma
CountriesUnited States
Collaborators--

Timeline

N/ARecruiting
202020212022202320242025202620272028
First PostedOct 3, 2019
Enrollment StartOct 22, 2019
Primary CompletionJun 1, 2028
TodayJul 2, 2026
Enrollment to primary: 8.6 yearsPosted 6.7 years agoPrimary completion in 1.9 years

Interventions

MR-guided Linacradiation

Radiation will be delivered on an MR-guided Linear Accelerator